Consensus Panel Recommendations for the Pharmacological Management of Breastfeeding Women with Postpartum Depression
Authors:
- Georgios EleftheriouGEGeorgios Eleftheriou
- Riccardo Zandonella CallegherRCRiccardo Zandonella Callegher
- Raffaella ButeraRBRaffaella Butera
- Marco De SantisMSMarco De Santis
- Anna Franca CavaliereACAnna Franca Cavaliere
- Sarah VecchioSVSarah Vecchio
- Cecilia LanziCLCecilia Lanzi
- Riccardo DavanzoRDRiccardo Davanzo
- Giovanna MangiliGMGiovanna Mangili
- Emi BondiEBEmi Bondi
- Lorenzo SomainiLSLorenzo Somaini
- Mariapina GalloMGMariapina Gallo
Open Access
- 26 April 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (5) , 551
Abstract
Introduction: Our consensus statement aims to clarify the use of antidepressants and anxiolytics during breastfeeding amidst clinical uncertainty. Despite recent studies, potential harm to breastfed newborns from these medications remains a concern, leading to abrupt discontinuation of necessary treatments or exclusive formula feeding, depriving newborns of benefits from mother’s milk. Methods: A panel of 16 experts, representing eight scientific societies with a keen interest in postpartum depression, was convened. Utilizing the Nominal Group Technique and following a comprehensive literature review, a consensus statement on the pharmacological treatment of breastfeeding women with depressive disorders was achieved. Results: Four key research areas were delineated: (1) The imperative to address depressive and anxiety disorders during lactation, pinpointing the risks linked to untreated maternal depression during this period. (2) The evaluation of the cumulative risk of unfavorable infant outcomes associated with exposure to antidepressants or anxiolytics. (3) The long-term impact on infants’ cognitive development or behavior due to exposure to these medications during breastfeeding. (4) The assessment of pharmacological interventions for opioid abuse in lactating women diagnosed with depressive disorders. Conclusions: The ensuing recommendations were as follows: Recommendation 1: Depressive and anxiety disorders, as well as their pharmacological treatment, are not contraindications for breastfeeding. Recommendation 2: The Panel advocates for the continuation of medication that has demonstrated efficacy during pregnancy. If initiating an antidepressant during breastfeeding is necessary, drugs with a superior safety profile and substantial epidemiological data, such as SSRIs, should be favored and prescribed at the lowest effective dose. Recommendation 3: For the short-term alleviation of anxiety symptoms and sleep disturbances, the Panel determined that benzodiazepines can be administered during breastfeeding. Recommendation 4: The Panel advises against discontinuing opioid abuse treatment during breastfeeding. Recommendation 5: The Panel endorses collaboration among specialists (e.g., psychiatrists, pediatricians, toxicologists), promoting multidisciplinary care whenever feasible. Coordination with the general practitioner is also recommended.Keywords
This publication has 194 references indexed in Scilit:
- Opioids in Breast Milk: Pharmacokinetic Principles and Clinical ImplicationsThe Journal of Clinical Pharmacology, 2018
- Modeling drug passage into human milkClinical Pharmacology & Therapeutics, 2016
- Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum WomenJAMA, 2016
- Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression FindingsJAMA Psychiatry, 2013
- Sertraline in paired blood plasma and breast-milk samples from nursing mothersHuman Psychopharmacology: Clinical and Experimental, 2000
- Excretion of Fluoxetine and Its Metabolite, Norfluoxetine, in Human Breast MilkThe Journal of Clinical Pharmacology, 1996
- Zolpidem excretion in breast milkEuropean Journal of Clinical Pharmacology, 1989
- Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patientsEuropean Journal of Clinical Pharmacology, 1988
- The depressed mother and her one-year-old infant: Environment, interaction, attachment, and infant developmentNew Directions for Child and Adolescent Development, 1986
- Pharmacokinetics and biotransformation of the new benzodiazepine, lormetazepam, in manEuropean Journal of Clinical Pharmacology, 1982